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ABSTRACT 25 
Bluetongue virus (BTV) is the causative agent of bluetongue, a major infectious disease of 26 
ruminants with serious consequences to both animal health and the economy. The clinical 27 
outcome of BTV infection is highly variable and dependent on a variety of factors related to 28 
both the virus and the host. In this study, we show that the BTV non-structural protein NS4 29 
favours viral replication in sheep, the animal species most affected by bluetongue. In 30 
addition, NS4 confers a replication advantage to this virus in primary sheep endothelial cells 31 
and in IFN-competent immortalized cell lines. We determined that in cells infected with a 32 
NS4 deletion mutant (BTV8ΔNS4) there is an increased synthesis of type I interferon 33 
(IFN) compared to cells infected with wild type BTV-8. In addition, using RNAseq, we show 34 
that NS4 modulates the host IFN response and downregulates mRNA levels of type I IFN and 35 
interferon stimulated genes. Moreover, using reporter assays and protein synthesis assays, 36 
we show that NS4 downregulates the activity of a variety of promoters such as the 37 
cytomegalovirus immediate early promoter, the IFN-β promoter and a promoter containing 38 
interferon-stimulated response elements (ISRE). We also show that the NS4 inhibitory 39 
activity on gene expression is related to its nucleolar localization. Furthermore, NS4 does 40 
not affect mRNA splicing or cellular translation. The data obtained in this study strongly 41 
suggest that BTV NS4 is an IFN-antagonist and a key determinant of viral virulence.  42 
 43 
IMPORTANCE 44 
Bluetongue is one of the main infectious diseases of ruminants and is caused by bluetongue 45 
virus (BTV), an arthropod-borne virus transmitted from infected to susceptible animals by 46 
Culicoides biting midges. Bluetongue has a variable clinical outcome that can be related to 47 
both virus and host factors. It is therefore critical to understand the interplay between BTV 48 
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and the host immune responses. In this study we show that a non-structural protein of BTV 49 
(NS4) is critical to counteract the innate immune response of the host. Infection of cells with 50 
a BTV mutant lacking NS4 results in increased synthesis of IFN-β and upregulation of 51 
interferon stimulated genes. In addition, we show that NS4 is a virulence factor for BTV by 52 
favouring viral replication in sheep, the animal species most susceptible to bluetongue.  53 
  54 
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INTRODUCTION 55 
Bluetongue virus (BTV) is the causative agent of bluetongue, a major infectious disease of 56 
ruminants with serious consequences to both animal health and the economy (1). 57 
Throughout the twentieth century, bluetongue has occurred almost exclusively in tropical 58 
and sub-tropical geographical areas (2). However, in the last two decades the geographical 59 
limits of the disease have expanded and BTV is now endemic in more temperate areas such 60 
as Southern and Central Europe (3). 61 
BTV is an arbovirus transmitted by Culicoides spp. biting midges and belongs to the Orbivirus 62 
genus within the Reoviridae (4, 5). The BTV genome consists of 10 dsRNA genome segments 63 
encoding for seven structural and four, possibly five, non-structural proteins (6-9). The core 64 
particle, formed by VP3 and VP7, encapsidates the viral genome segments, each associated 65 
with a replicase complex comprising VP1, VP4 and VP6 (6, 10-12). VP2 and VP5 constitute 66 
the outer capsid of the BTV virion and are responsible for cell attachment and entry (13-15). 67 
VP2 is the most variable BTV protein and determines the virus serotype, of which there are 68 
27 described to date (16-19). 69 
The BTV non-structural proteins play fundamental roles in virus replication. NS1 forms 70 
tubules in the cytoplasm of BTV infected cells and favours viral protein synthesis (20-22). 71 
NS2 is the major component of viral inclusion bodies (23-25), while NS3/NS3A play a critical 72 
role in virus intracellular trafficking and egress (26, 27). NS3 has also been shown to 73 
downregulate transcription from the IFN-β promoter in reporter assays (28). A putative fifth 74 
non-structural protein may be expressed from a conserved small open reading frame in 75 
segment 10 (29). 76 
NS4 is a small protein (77-79 amino acid residues) encoded by an open reading frame (ORF) 77 
in genome segment 9 overlapping the larger ORF encoding for VP6 and with nucleolar 78 
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localization. Although NS4 has been shown to confer a replication advantage to BTV in cells 79 
treated with interferon, it is dispensable for BTV replication in IFN incompetent cell lines 80 
and has no impact on pathogenicity in IFNAR-/- mice (8, 9).  81 
The clinical outcome of BTV infection is highly variable and dependent upon a variety of 82 
viral, host and likely environmental factors (30-35). Understanding the interplay between 83 
BTV and the host immune response will be central to identifying the virus and host 84 
determinants of disease susceptibility.  85 
In order to establish a successful infection, BTV must overcome both physical and innate 86 
immune barriers. One of the key innate immune mechanisms to fight viral infections is the 87 
IFN system (36). Mammalian cells possess pattern-recognition receptors that detect 88 
incoming pathogen signatures and induce the synthesis and secretion of IFN-β. Secreted IFN 89 
signals in both an autocrine and paracrine fashion, leading to the transcription of hundreds 90 
of IFN-stimulated genes (ISGs), some of which have a direct or indirect antiviral effect (37). 91 
BTV is known to induce an IFN response, both in vitro and in vivo, and consequently it must 92 
possess countermeasures that allow the virus to replicate in the face of this host response 93 
(8, 38-43). Evidence to date suggests that BTV NS3 and NS4 are the viral proteins most likely 94 
responsible for the disruption of the cellular innate immune response to BTV infection (8, 95 
28). 96 
In this study, we investigated the interaction of BTV and the IFN response of the host. We 97 
demonstrate that NS4 is an important virulence factor in sheep, a natural host of BTV 98 
infection, and acts as an interferon antagonist.  99 
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MATERIALS AND METHODS 100 
 101 
Cell cultures. Vero, BHK21 and BSR cells (a clone of BHK21, kindly provided by Karl K. 102 
Conzelmann) (44) were grown in Dulbecco’s modified Eagle’s medium (DMEM) 103 
supplemented with 10% fetal bovine serum (FBS). CPT-Tert cells are sheep choroid plexus 104 
cells immortalized with the simian virus 40 (SV40) T antigen and human telomerase reverse 105 
transcriptase (hTERT) (45). CPT-Tert cells were grown in Iscove’s modified Dulbecco’s 106 
medium (IMDM), supplemented with 10% FBS. A549 cells are derived from a human lung 107 
adenocarcinoma and were grown in DMEM supplemented with 10% FBS. All cell lines were 108 
cultured at 37°C in a 5% CO2 humidified atmosphere. 109 
Primary ovine endothelial (ovEC) cells were obtained as previously described (46). ovEC 110 
were seeded in 12-well plates and maintained in a low oxygen incubator (37°C, 5% CO2 and 111 
3% O2). In this study, ovEC were passaged once before being used and cultured at 37°C in a 112 
5% CO2 humidified atmosphere. 113 
Viruses. Wild type BTV8 (BTV8wt) and a NS4 deletion mutant (BTV8ΔNS4) viruses used in 114 
this study were obtained by reverse genetics as described previously (8, 47). Virus stock 115 
titres were determined by standard plaque assays using CPT-Tert cells (48). The defective 116 
interfering-rich (DI-rich) preparations of Sendai virus (SeV, Cantell strain) was generated by 117 
sequentially passaging the virus at high MOI as previously described (49). 118 
Encephalomyocarditis virus (EMCV) was used in interferon protection assays (see below) 119 
and was prepared as previously described (50). 120 
Virus replication curves. Replication curves were carried out in either ovEC or A549 cells. 121 
Cells were infected with the appropriate virus (MOI = 0.01) and supernatants were collected 122 
at 24, 48 and 72h post-infection (pi). Supernatants were subsequently titrated by endpoint 123 
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dilution analysis on BSR cells using the method of Reed and Muench and expressed as log10 124 
(TCID50/ml) (51). Each experiment was performed independently in triplicate using at least 125 
two different stocks of each virus. 126 
Ethical Statement. All animal experimental procedures carried out in this study were 127 
approved by the ethical committee of the Istituto Zooprofilattico Sperimentale dell'Abruzzo 128 
e Molise “G. Caporale” (Teramo, Italy) (protocol no. 11427/2012) and further approved by 129 
the Italian Ministry of Health (Ministero della Salute) in accordance with Council Directive 130 
86/609/EEC of the European Union and the Italian D.Igs 116/92. 131 
In vivo pathogenicity studies. Experiments were carried out using 15 sheep (Italian mixed-132 
breed) in an insect-proof isolation unit. Before inoculation, all animals were confirmed to 133 
have no antibodies against BTV using a blocking enzyme-linked immunosorbent assay 134 
(ELISA) as previously described (52). The absence of BTV genome in blood samples of each 135 
animal was also confirmed by qRT-PCR as already described (30). Animals (n=5 per group) 136 
were infected with 5 ml of either BTV8wt or BTV8ΔNS4 (2×106 PFU in total) by multiple 137 
intradermal inoculations in the inner leg and prescapular areas. Negative controls were 138 
inoculated with 5 ml of mock-infected cell supernatants. Body temperature was recorded 139 
daily, beginning a week before inoculation, until day 14 pi and subsequently at days 17, 21, 140 
and 28. Fever was defined as rectal temperature above 40°C. EDTA blood samples were 141 
collected daily from all animals for 14 days pi and thereafter at days 17, 21, and 28, when 142 
the experiment was terminated. Blood samples were analyzed for the presence of viremia 143 
by qRT-PCR as previously described (30). Sera were collected from each animal on the day of 144 
the inoculation (day 0) and then at days 7, 14, 21, and 28 pi. The presence of neutralizing 145 
antibodies in infected sheep against BTV8 was assessed by virus neutralization assay as 146 
previously described (53). 147 
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Plasmids and antisera. The open reading frame encoding NS4 was either amplified by PCR 148 
(BTV8 NET2006/04 (GenBank Accession number JX680455), BTV1 RSArrrr/01 (JX680465), 149 
BTV-2IT(L) (JN255870)), or synthesised commercially (Genscript), ((BTV-2RSA(WT) 150 
(JN255930), BTV-9IT(L) (JN255910), BTV1SASEG9 (D10905), BTV25 (EU839845), BTV26 151 
(JN255161)) and cloned into the pCI mammalian expression vector (Promega). BTV10 152 
segment 8 (NC006007) was synthesized commercially (Genscript) and cloned into pCI. All 153 
plasmids used in this study were sequenced before use. Plasmid pCMV-luc was obtained by 154 
inserting the firefly luciferase (FLuc) open reading frame into pCDNA3.1 (Invitrogen) as 155 
previously described (54). pRL-CMV (Promega) is similar to pCMV-luc but contains an intron 156 
before the Renilla luciferase gene. p125Luc expresses FLuc under the control of the IFN-β 157 
promoter (55). pISRE-Luc (Promega) contains five copies of the ISRE-binding sequence (56) 158 
located upstream of the TATA like promoter region from the herpes simplex virus thymidine 159 
kinase (HSV-TK) promoter. 160 
Antisera used in this study included polyclonal rabbit antisera raised against the BTV NS4 161 
and NS2 proteins as previously described (8). Antibodies against B23 (Sigma), α-tubulin 162 
(Sigma), IRF-3 (clone FL-425, Santa Cruz) and NF-κB p65 (clone D14E12, cell signalling) were 163 
obtained commercially. 164 
In vitro RNA transcription. Capped and polyadenylated RNA for use in luciferase assays was 165 
generated using the mMESSAGE mMACHINE® T7 Ultra Kit as recommended by the 166 
manufacturers (Ambion, Life Technologies), using linearised pCMV-luc or pRL-CMV as a 167 
template. 168 
An RNA control (named EU-Luc-pA) for use in RNAseq and qRT-PCR experiments was 169 
obtained as follows. Linearized pCMV-luc was transcribed using the Megascript® T7 kit 170 
(Ambion, Life Technologies) according to the manufacturer’s instructions, with the 171 
9 | P a g e  
 
exception that the transcription reaction mix was supplemented with an analogue of uridine 172 
(5-Ethynyl Uridine [EU], Invitrogen, Life Technologies). The RNA was then polyadenylated 173 
following the polyA tailing procedure of the mMESSAGE mMACHINE® T7 Ultra Kit. All in vitro 174 
transcribed RNA was recovered using the RNeasy Mini Kit (Qiagen). 175 
Labelling and extraction of nascent RNA for transcriptomic analyses. A549 cells were 176 
seeded in 6-well plates, incubated at 37°C for 24h and mock-infected or infected with 177 
BTV8wt or BTV8ΔNS4 at a MOI of 4. At 8, 12 and 16h post-infection (pi), nascent RNA was 178 
labelled with 0.4 mM EU for 90 min. Cells were lysed with 1 ml of TRIzol® spiked with 1 ng of 179 
EU-Luc-pA. Total RNA was then extracted using the TRIzol method and further purified using 180 
the RNeasy mini spin columns (Qiagen), including an on-column DNase I digestion step 181 
(Qiagen) according to the manufacturer’s protocol. 182 
RNAseq. 4.5 μg of total RNA was enriched by selectively depleting rRNA using the 183 
RiboMinus™ Eukaryote Kit v2 (Ambion, Life Technologies). The EU-labelled RNA was 184 
specifically linked to an azide-modified biotin by a chemical reaction and then captured on 185 
streptavidin magnetic beads using the Click-iT® Nascent RNA Capture Kit (Molecular probes, 186 
Life Technologies). Biotin-labelled RNA (attached to the magnetic beads) was fragmented 187 
and subsequently used to construct libraries using the Ion Total RNAseq v2 Kit (Life 188 
Technologies) as described by the manufacturer. Amplified libraries were size-selected using 189 
the E-Gel size select system (Life Technologies) and assessed using a Tapestation (Agilent). 190 
Libraries were quantified using the Qubit HS dsDNA assay (Life Technologies) and sequenced 191 
using the Ion Proton sequencer (Life Technologies). The sequence reads were processed 192 
according to the Tuxedo pipeline (57). Read quality was first assessed using FastQC (58). 193 
Tophat2 and Bowtie2 were used to map short reads against the Homo Sapiens genome 194 
(UCSC hg19) and a list of differentially expressed genes was generated using CuffDiff2 195 
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(genes with Benjamini Hochberg P-value ≤ 0.05 were considered significant) (59, 60). 196 
Canonical pathway analysis was performed using the Ingenuity Pathway Analysis (IPA) 197 
software (Qiagen) by submitting the differentially expressed (DE) gene datasets (Tables S1-198 
3) and using the default parameters. 199 
qRT-PCR For qRT-PCR analysis, mRNA was purified from the total RNA fraction using the 200 
Dynabeads® mRNA DIRECT™ Kit (Ambion, Life Technologies) according to the 201 
manufacturer’s instructions, before capturing EU-labelled RNA as described above. RNA 202 
captured on the Streptavidin beads was used directly as a template for cDNA synthesis using 203 
the SuperScript® VILO™ cDNA synthesis Kit (Invitrogen, Life Technologies). qPCR was 204 
performed using the Brilliant III Ultra Fast QPCR Master Mix (Agilent) to detect a selection of 205 
ISGs, housekeeping genes and the spiked EU-Luc-pA. Sequences of primers and probes are 206 
available upon request. Samples were run on an Mx3005P (Stratagene) PCR machine and 207 
analyzed using the MxPro software (Stratagene). Mock-infected cells were used as a 208 
calibrator against which the infected cells were compared. The EU-Luc-pA RNA was used as 209 
an exogenous control to normalise the results.  210 
Interferon protection assays. Interferon protection assays were performed as previously 211 
described (46). Briefly, OvEC cells were first seeded in 12-well plates and incubated for 2 212 
days. Cells were then mock-infected or infected with the indicated virus at a MOI of 4 and 213 
the medium was collected 16h post-infection. Cell culture supernatants were treated with 214 
UV light to inactivate any virus. CPT-Tert cells were incubated with two-fold dilutions of the 215 
medium for 24h, before infecting them with EMCV for 72h. The level of IFN (expressed as 216 
“international units”, IU) was calculated by monitoring wells that were protected from cell 217 
death induced by EMCV and comparing them to known amounts of universal IFN. 218 
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Western blotting. Protein expression was assessed from total cell lysates by sodium 219 
dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting using 220 
the various antisera indicated above and as previously described (61). For quantitative 221 
western blotting, primary antibodies were detected using fluorescently labelled secondary 222 
antibodies (DyLight, Thermo Scientific) in a LI-COR Odyssey scanner. Bands were quantified 223 
with the Odyssey software (LI-COR Biosciences). 224 
Metabolic radiolabeling. ovEC cells were mock-infected or infected with BTV8wt or 225 
BTV8ΔNS4 at a MOI of 4. At the time points indicated, cells were incubated at 37°C for 30 226 
min in media lacking methionine. Nascent proteins were labelled for 2 h with 35S 227 
methionine/cysteine (0.8 MBq/ml; PerkinElmer) after which they were resuspended in 228 
sample buffer (60 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 2.5% β-mercaptoethanol, 229 
0.01% bromophenol blue) and the proteins separated by SDS-PAGE as described above. 230 
Visualisation of labelled proteins was achieved by exposure to a Storm840 Phospho-imager 231 
(Molecular Dynamics) or to X-ray film. Band intensities were determined using ImageQuant 232 
software (Amersham). 233 
Luciferase assays. CPT-Tert cells grown in 24-well plates were co-transfected using 234 
Lipofectamine 2000 (Invitrogen) with 100ng of pCMV-luc or pRL-CMV along with 100 to 400 235 
ng of the indicated pCI plasmids expressing NS4. A similar procedure has been performed to 236 
co-transfect 200 ng of in vitro transcribed RNA expressing firefly luciferase (see above) and 237 
the appropriate expression plasmids as indicated (100 to 400 ng). When using p125Luc (50 238 
ng) and pISRE-luc (400 ng), 293T cells were either infected with DI-rich preparations of SeV 239 
or treated with 200 U/ml of Universal Interferon (UIFN, PBL InterferonSource) 4h post 240 
transfection, before incubating for a further for 18h.  241 
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The total amount of plasmid DNA transfected used was 500ng for all experiments, using the 242 
empty pCI plasmid to balance each transfection. Luciferase activity was detected 22h post-243 
transfection using the Luciferase or Dual Luciferase Assay System (Promega) as described by 244 
the manufacturer. The percentage of luciferase was determined by assigning the luciferase 245 
activity or luminescence (expressed as relative light unit, RLU) detected in control cells (i.e. 246 
transfected with pCMV-luc and an empty pCI plasmid only) as 100%. Constitutive promoters 247 
as transfection controls could not be used as NS4 affects gene expression. However, each 248 
experiment was repeated independently at least three times with each samples assessed in 249 
in triplicate. For each experiment, at least two independent plasmid preparations were 250 
used. Relative lights units for each sample were always at least 100 fold above background. 251 
In addition, in some experiments, 5 ng of in vitro transcribed RNA encoding renilla luciferase 252 
were used as additional internal control.  253 
Confocal microscopy. Experiments were performed using CPT-Tert or A549 cells cultured in 254 
two-well glass chamber slides (Lab-Tek, Nalge Nunc International). Cells were either 255 
transfected with the appropriate plasmids or infected with the indicated viruses (MOI = 4) 256 
for 16-22h. Cells were washed with PBS and fixed with 5% formaldehyde for 15 min. Fixed 257 
cells were then processed as described previously (62) and incubated with the appropriate 258 
antisera. Secondary antibodies were conjugated with either Alexa Fluor 488 or Alexa Fluor 259 
594 (Invitrogen, Molecular Probes). Slides were mounted using Vectashield mounting 260 
medium with DAPI (4’,6-diamidino-2-phenylindole, Vector Laboratories). Slides were 261 
analysed and images collected using a Leica TCS SP2 confocal microscope. 262 
 263 
  264 
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RESULTS 265 
BTV8ΔNS4 is attenuated in experimentally infected sheep. In a previous study, we showed 266 
that a BTV8 NS4 deletion mutant (BTV8ΔNS4) is as virulent as BTV8 wt in experimental 267 
mouse models of infection (8). Here we wanted to determine whether NS4 influenced 268 
virulence in sheep, the natural host of BTV infection. Therefore, we experimentally infected 269 
sheep with BTV8wt or BTV8ΔNS4. Sheep infected with BTV8wt showed an elevation of body 270 
temperature from day 6 to day 8 pi (Fig. 1, top panels). BTV RNA was detectable at day 4 pi, 271 
reached a plateau from day 6 to 10 pi and was followed by a slow decrease. Viremia 272 
remained detectable until the end of the experiment. In contrast, animals infected by 273 
BTV8ΔNS4 did not develop pyrexia and displayed a delayed onset and lower levels of 274 
viremia. BTV RNA was below the detection levels in 4 of the 5 inoculated sheep at 4 weeks 275 
pi when the experiment was stopped (Fig. 1, middle panels). Between days 4 and 28 pi, the 276 
average levels of BTV RNA were between 102 and 105 fold higher in sheep infected with 277 
BTV8wt compared to those infected with BTV8ΔNS4. As expected, all BTV infected animals 278 
developed neutralizing antibodies from day 7 pi (Fig. 1, lower panels). Altogether, these 279 
data show that BTV8ΔNS4 is attenuated in sheep and suggest that NS4 is a virulence factor 280 
in vivo. 281 
Replication kinetics of BTV8wt and BTV8ΔNS4 in primary ovine endothelial cells and 282 
human A549 cells. We showed previously that BTV8ΔNS4 replicates as efficiently as BTV8wt 283 
in immortalized cell lines, such as hamster BSR and sheep CPT-Tert cells (8) but these cell 284 
lines do not possess an intact IFN response to viral infections (44, 45). Hence, we compared 285 
the replication kinetics of BTV8wt and BTV8ΔNS4 in primary ovine endothelial cells (ovEC). 286 
BTV8wt reached titers approximately 20 fold higher than BTV8ΔNS4 at 72h pi (Fig. 2A). 287 
Similarly, BTV8wt reached titers nearly 60 fold higher than BTV8ΔNS4 in the IFN-competent 288 
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human cell line A549 (Fig. 2A). These data demonstrate that the presence of NS4 confers a 289 
replication advantage to BTV8 in cells that are capable of mounting an antiviral response. 290 
NS4 inhibits IFN release, but not virus sensing, in infected cells. Given the data obtained 291 
above and the previously published observation that NS4 confers a replication advantage to 292 
BTV in cells pre-treated with IFN (8), we next sought to determine whether NS4 impacted 293 
the level of IFN released into the supernatant of infected cells. Primary ovEC were infected 294 
at a MOI of 4 with either BTV8wt or BTV8ΔNS4. 16 h pi the level of IFN in cell culture media 295 
was measured using an IFN protection assay. BTV8ΔNS4 infected cells had, on average, 13 296 
times more IFN (p<0.001) in their supernatants than BTV8wt infected cells (Fig. 2B).  297 
These results could potentially be explained by NS4 affecting either the sensing of viral 298 
infection, or transcription and/or the synthesis/secretion of IFN into the supernatant. The 299 
first step in IFN-β expression is the recognition of pathogen-associated molecular patterns 300 
(PAMPs) by various host pattern recognition receptors, which results in the translocation of 301 
the transcription factors IRF-3 and NFκB into the nucleus (37). In order to determine 302 
whether NS4 impacted supernatant levels of IFN by interfering with this process, we 303 
infected A549 cells at a MOI of 4 for 16h and assessed the nuclear translocation of IRF-3 and 304 
NFκB by confocal microscopy. The cellular localization of IRF-3 and NFκB in mock-infected 305 
cells was exclusively cytoplasmic (Fig. 3) while stimulation with TNFα (tumor necrosis factor 306 
α) used as positive control resulted in nuclear translocation of these proteins in essentially 307 
100% of the cells (not shown). In contrast, between 25 and 35% of cells infected by BTV8wt 308 
showed translocation of IRF-3 and NFκB into the nucleus. BTV8ΔNS4 was found to induce 309 
similar levels of translocation as BTV8wt, suggesting that NS4 does not prevent either PAMP 310 
recognition by the host cells or translocation of IRF-3 and NFκB. NS2 immunolabelling 311 
confirmed similar levels of infection in cells infected with BTV8wt or BTV8∆NS4 (Fig. 3). 312 
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NS4 downregulates IFN-β and interferon stimulated genes (ISGs) mRNA levels. Next, we 313 
carried out RNAseq analysis on IFN-competent A549 cells infected with either BTV8wt or 314 
BTV8ΔNS4 in order to further characterize the activity of NS4. Mock-infected A549 cells 315 
were used as negative controls. Libraries were prepared from nascent RNA metabolically 316 
labelled with a uracil analogue for 90 minutes at 12h pi (Fig. 4A), and sequenced on an Ion 317 
Proton sequencer (Life Technologies, Thermo Fisher). On average, 64.58 million reads per 318 
sample were generated (Phred quality > 20). We found 2863 differentially expressed genes 319 
in cells infected by BTV8wt compared to mock-infected cells, out of which 1055 were 320 
downregulated and 1808 were upregulated (Fig. 4B). In comparison, fewer genes (n=2292) 321 
were found to be differentially expressed in cells infected by BTV8ΔNS4 compared to mock-322 
infected cells, with 752 of them being downregulated and 1540 upregulated. The entire list 323 
of differentially expressed genes in BTV8wt and BTV8ΔNS4 infected cells is presented in 324 
Tables S1-S3. CH25H (cholesterol 25-hydroxylase, a known ISG) was found to be the most 325 
upregulated gene in BTV8ΔNS4 infected cells. 117 genes were upregulated in BTV8ΔNS4-326 
infected cells compared to BTV8wt-infected cells (Table S3). Of these 117 genes, 102 were 327 
either IFN genes or ISGs according to the Interferome database (63). IFN-β, IFN-λ1, IFN-λ2 328 
and IFN-λ3 were among the 6 highest upregulated genes in BTV8ΔNS4 infected cells (87 to 329 
136 fold higher in comparison to mock-infected cells) (Table 1). Interestingly, more genes 330 
were strongly upregulated (fold change >32) in BTV8ΔNS4 (n=33) compared to BTV8wt 331 
infected cells (n= 7). These genes included MX1 and -2, IFIT1, -2 and -3, OASL and other well 332 
characterised ISGs. However, all of the 33 genes highly upregulated in BTV8ΔNS4-infected 333 
cells were also upregulated (albeit at a lower level) in BTV8wt infected cells (Table 1). IFN-β 334 
for example, was also upregulated (17 fold) in BTV8wt infected cells. No major differences in 335 
the levels of expression in BTV8wt and BTV8ΔNS4 infected cells were observed in those 336 
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genes with the highest levels of downregulation (Table 2). We validated the RNAseq analysis 337 
by qRT-PCR on selected genes found equally or differentially expressed in mock- and 338 
infected cells. Relative mRNA levels of IFNB1, IFIT1, B2M, ACTB, ANXA1 and TBP determined 339 
by RT-qPCR reflected the patterns of expression observed in the RNAseq analyses (Fig. 4C). 340 
The Ingenuity Pathway Analysis software (IPA; Qiagen) was used to compare the 341 
representation of canonical pathways comparisons between infected vs uninfected cells (Fig 342 
5A-B), and cells infected with either BTV-8wt or BTV8ΔNS4 (Fig 5C). Most of the pathways 343 
were involved in the cellular immune response, cytokine signalling, inflammatory response, 344 
apoptosis and pathogen related signalling. Consistent with the RNAseq dataset, pathways 345 
relating to the innate immune response were particularly evident when comparing 346 
BTV8ΔNS4 with BTV8wt (Fig. 5C). 347 
The availability of the transcriptome of cells infected by BTV8wt and BTV8ΔNS4 also 348 
provided additional information regarding the possible influence of NS4 on mRNA 349 
maturation. Comparable proportions of reads containing intron sequences were found in 350 
mock-infected cells or in cells infected with BTV8wt or BTV8ΔNS4 (data not shown). In 351 
addition, we also quantified how many reads finished with 8 or more adenines, assuming 352 
these reads as representative of polyadenylated mRNAs. Comparable percentages of polyA 353 
reads were obtained in the three conditions tested, suggesting that NS4 was not associated 354 
with a global defect in mRNA polyadenylation (data not shown).  355 
NS4 modulates the activity of a wide range of promoters. We next assessed the ability of 356 
BTV-8 NS4 to reduce the activity of basal promoters, such as the CMV immediate early 357 
promoter, and promoters of genes involved in the host innate immune response (IFN-β and 358 
ISRE-containing promoters). 293T cells were co-transfected with a plasmid expressing either 359 
BTV NS4 or NS2, and a FLuc reporter plasmid driven by either the CMV promoter, the IFN-β 360 
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promoter or a promoter containing ISRE elements (Fig. 5). 4h post-transfection, cells 361 
transfected with the IFN-β promoter were stimulated with Sendai virus while cells 362 
transfected with ISRE-containing promoter were stimulated with universal IFN (200 U/ml). 363 
NS4, unlike NS2, was able to reduce between 40 and 60% the activity of both CMV, IFN-β 364 
and ISRE promoters (Fig. 6).  365 
To further investigate the ability of NS4 to block host gene expression, sheep cells were co-366 
transfected with an expression plasmid for FLuc, under the control of the CMV immediate-367 
early promoter along with a variety of expression plasmids expressing BTV NS4, or an empty 368 
plasmid (also containing a CMV promoter) as a control (Fig. 7). NS4 is well conserved among 369 
the BTV serotypes/strains identified to date (8). The only exception was a strain of BTV-1 370 
(GenBank accession number D10905 submitted in 1992) and the more divergent BTV-25 and 371 
BTV-26 strains (EU839845 and JN255161) which showed only 77.9%, 76.6% and 75.3% 372 
identity to BTV-8 NS4, respectively (Fig. 7A). All of the NS4 proteins tested were able to 373 
reduce FLuc expression with the notable exception of the NS4 from the BTV/D10905 (Fig. 374 
7B). Interestingly, the NS4 protein of BTV-1 D10905 displayed a different mobility from 375 
other NS4 proteins by SDS-PAGE that could be explained by the presence of considerable 376 
differences in its basic residues in the N-terminus. In addition, using BTV-8 NS4 we showed 377 
that gene expression inhibition by NS4 was dose dependent (Fig. 7C).  378 
In a previous study, we showed that NS4 localizes in the nucleoli of infected or transfected 379 
cells (8). Interestingly, BTV-1/D10905 NS4 was the only variant which failed to localise to the 380 
nucleoli of sheep CPT-Tert cells (Fig. 7D), suggesting that nucleolar localization may be 381 
critical for the activity of this non-structural protein. 382 
NS4 is not the only viral protein involved in host cell protein shutoff. It is well established 383 
that BTV induces protein synthesis shutoff in infected cells (64-66). Conceivably, a reduced 384 
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level of IFN (both mRNA and proteins) observed in cells infected with BTV8wt could reflect 385 
the general virus-induced shut off of protein synthesis. In order to test this hypothesis, we 386 
metabolically radiolabelled nascent proteins in ovEC cells mock-infected, or infected with 387 
either BTV8wt or BTV8ΔNS4. As expected, we observed decreased levels of 35S-labelled 388 
methionine/cysteine proteins in BTV8wt-infected cells compared to mock infected cells 389 
(particularly evident at 18 and 26h pi), confirming previously published data (Fig. 8) (65, 66). 390 
Protein synthesis shutoff was also evident in BTV8ΔNS4 infected cells, although at 391 
somewhat reduced levels compared to BTV8wt. In order to quantify the reduction in protein 392 
synthesis during viral infection we used phosphoimaging and measured the signal intensity 393 
of a prominent band present in all samples (Fig. 8A, black arrow). The signal intensity of 394 
actin in BTV8wt-infected cells relative to mock-infected cells (taken as 100%) reduced 395 
progressively to 69% at 10h pi, 37% at 18h pi and 2% at 24h pi, by which point cytopathic 396 
effect was apparent. On the other hand, the signal intensity of actin was 82%, 56% and 12%. 397 
Hence, these data suggest that host protein shutoff induced by BTV occurs largely 398 
independently of NS4, although the latter may contribute to this phenomenon. 399 
BTV-8 NS4 does not influence mRNA splicing nor translation. We also assessed the impact 400 
of NS4 on RNA transcript splicing. CPT-Tert cells were transfected with the pRL-CMV vector, 401 
which is driven by the CMV immediate early promoter and contains the RLuc gene 402 
downstream of an intron. In this assay, NS4 retained the ability to inhibit the expression of 403 
the reporter gene in a dose-dependent manner (Fig. 8B), indicating that NS4 does not affect 404 
mRNA splicing and confirming the data obtained by RNAseq described above. Cells were 405 
also co-transfected with in vitro transcribed RNA encoding FLuc and an expression plasmid 406 
for the BTV8 NS4, in order to determine whether NS4-induced inhibition of protein 407 
expression could also occur at translational level (Fig. 8C). Increasing levels of NS4 did not 408 
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interfere with the level of FLuc activity driven by RNA, as opposed to the activity driven by 409 
plasmid DNA used as control, suggesting that the inhibition mediated by NS4 is happening 410 
most likely at transcriptional and not at the translational level. 411 
  412 
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DISCUSSION 413 
In this study we showed that NS4 is an IFN-antagonist and a virulence factor for BTV. BTV 414 
NS4 deletion mutants replicate as efficiently as wild type viruses in cell lines that lack a 415 
competent innate immune system and are lethal to IFNAR-/- mice (8). In contrast, here we 416 
demonstrated that NS4 facilitates BTV replication in vitro in IFN competent cells, and in vivo 417 
in sheep, the animal species most affected by bluetongue. 418 
BTV induces a type 1 IFN response in vivo and in vitro (38-42). Our data strongly suggest that 419 
NS4 is required by the virus to help overcome the cellular innate antiviral responses. 420 
Reporter assays revealed that NS4 can inhibit transcription from a variety of mammalian 421 
and viral promoters, whilst having little if any direct impact on mRNA editing or translation. 422 
However, NS4 does appear to influence the extent of the host IFN response as supernatants 423 
of primary sheep endothelial cells infected with BTV8ΔNS4 contained more IFN than 424 
supernatants collected from BTV8wt infected cells; a result which may explain the more 425 
efficient growth of BTVwt in IFN competent cells. These results were supported by RNAseq 426 
analyses of nascent RNA isolated from infected and mock-infected cells. Genes relating to 427 
the innate immune system were among the highest upregulated genes in BTV8ΔNS4 428 
infected cells, even if some of them were also found upregulated in BTV8wt infected cells, 429 
suggesting that NS4 is not by itself sufficient to inhibit entirely the host IFN response. Most 430 
of the genes that were specifically upregulated in BTV8ΔNS4 infected cells, as compared to 431 
BTV8wt infected cells, were ISGs including well characterised antiviral factors. 432 
Overall, the data obtained in this study indicate that NS4 exerts its effect upon the antiviral 433 
host response at a point upstream of RNA editing and translation. Interestingly, NS4 434 
possesses features of a transcription factor of the bZip family, with a basic domain followed 435 
by a leucine zipper motif (67) and it has been suggested to have the ability to bind DNA 436 
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using DNase protection assays (9). Our reporter assays, showing that NS4 inhibits 437 
transcription from a variety of promoters, including IFN-β and an ISRE-containing promoter, 438 
suggest that this protein may inhibit cellular transcription. In a previous study we showed 439 
that NS4 displays a nucleolar localization in infected cells (8). Thus, a direct interaction of 440 
NS4 with transcription factors and/or chromatin, resulting in the downregulation of cellular 441 
transcription is a possible mechanism of action for this protein. In support of this 442 
hypothesis, we found that the NS4 of a BTV-1 strain that did not show nucleolar localization 443 
was not able to modulate gene expression in reporter assays. It is also possible that NS4 444 
inhibits IFN-β activation before transcription. Nuclear translocation of IRF-3 and NFκB 445 
appeared to occur at similar levels in both BTVwt and BTV∆NS4 infected cells, suggesting 446 
that NS4 does not prevent PAMP recognition by the host cells. However, it is possible that 447 
IRF-3 or NF-kB could be inhibited by NS4 in the nucleus. It is important to note that, in a 448 
previous study, we showed that NS4 confers a replication advantage to BTV in cells pre-449 
treated with type I IFN, highlighting its ability to counteract the innate immune response 450 
after IFN activation. Hence, it is less that NS4 blocks PAMP recognition and subsequent 451 
signalling. More studies will be necessary to fully dissect how the NS4 counteracts the host 452 
innate immune system. Obviously NS4, like other non-structural proteins of different 453 
viruses, might have different functions and antagonise the IFN response via multiple 454 
mechanisms. For example, the NS1 protein of Influenza A viruses inhibits IFN production by 455 
blocking IRF3 and NF-κB activation, and mRNA maturation (68, 69).  456 
It has been known for at least three decades that BTV induces host protein synthesis 457 
shutdown (22, 64, 65). Recent studies suggest that BTV NS1 favours viral RNA translation 458 
and therefore competes with cellular protein synthesis (22). A key difference between 459 
mammalian and BTV transcripts is the lack of a polyA tail. The NSP3 protein of Rotaviruses 460 
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(also members of the Reoviridae) acts in a similar fashion and outcompetes the polyA 461 
binding protein of cells, thus biasing translation of viral transcripts (70, 71). It remains 462 
possible that a similar mechanism may exist for BTV. Our data, obtained in metabolically 463 
labelled cells, confirm that BTV induces host protein synthesis shutdown and also 464 
establishes that this occurs largely independently of NS4. Hence, other BTV proteins might 465 
also play a similar role in the shutoff of host cell protein synthesis or function in different 466 
ways as IFN antagonists. For example, NS3 is believed to modulate IFN induction 467 
downstream of RIG-I and upstream of IKKε activation. Therefore, NS3 and NS4 may 468 
potentially act synergistically to counteract the innate immune system (28). In addition, it 469 
has also been shown that BTV inhibits the IFN signalling pathway by downregulating key 470 
components of the JAK/STAT pathway: JAK1 and TYK2 (43). The downregulation of 471 
JAK1/TYK2 may be the result of a specific interaction with a BTV protein and/or due to the 472 
general host protein synthesis shutdown induced by this virus. We did not find either of 473 
these two genes to be differentially expressed in BTV8wt or BTV8ΔNS4 infected cells. 474 
In this study, we showed that BTV8ΔNS4 infected sheep display lower levels of viremia, 475 
lasting for shorter periods of time, compared to the viremia observed in animals infected 476 
with BTV8wt. The levels and duration of viremia in infected animals are essential factors for 477 
successful transmission between the mammalian hosts and the intermediate arthropod 478 
vectors. As mentioned above, BTV infection can result in a lethal hemorrhagic fever in some 479 
animals while in others the virus induces a mild febrile illness or even a clinically unapparent 480 
infection. The data obtained in this study provide evidence that viral proteins modulating 481 
the host innate immune response play a significant role in viral pathogenesis. This study lays 482 
the foundations for a deeper understanding of the mechanisms by which BTV antagonises 483 
the IFN system, in turn helping us to define the molecular determinants of BTV virulence.  484 
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 691 
Table 1. Top 33 upregulated genes in BTV infected compared to mock-infected A549 cells. 692 
 BTV8ΔNS4 vs Mock BTV8wt vs Mock 
Gene Rank* Fold change Rank Fold change 
CH25H U1 142.3 U18 23.6 
IFNB1 U2 136.4 U41 17.5 
IFNL1 U3 105.6 U11 28.8 
IFNL2 U4 91.0 U68 14.1 
MX1 U5 88.6 U38 17.8 
IFNL3 U6 87.7 U98 12.0 
OASL U7 87.6 U13 28.3 
IFIT2 U8 84.7 U14 25.9 
RSAD2 U9 78.7 U50 16.3 
IFIT1 U10 75.9 U36 18.2 
CXCL11 U11 71.6 U24 21.5 
IFIT3 U12 71.0 U40 17.6 
CMPK2 U13 64.1 U112 11.2 
IFI44 U14 63.4 U25 21.4 
MX2 U15 61.8 U76 13.6 
CCR4 U16 56.3 U17 24.0 
IFI27 U17 49.7 U170 8.9 
DDX58 U18 48.4 U115 11.0 
OAS2 U19 46.1 U5 33.6 
IFIH1 U20 45.5 U22 21.9 
CA1 U21 45.0 U9 30.9 
ISG15 U22 43.7 U78 13.4 
FOSB U23 43.6 U3 35.0 
EGR2 U24 42.5 U8 31.8 
FOS U25 39.9 U15 25.3 
IL8 U26 39.3 U29 19.8 
KLRC2 U27 36.8 U10 29.0 
EGR1 U28 36.1 U6 32.9 
SLC1A3 U29 35.9 U46 16.7 
EGR4 U30 35.7 U59 14.9 
BATF2 U31 33.5 U548 4.3 
HERC5 U32 32.4 U69 14.0 
IFI6 U33 32.3 U303 6.2 
 693 
*Rank of upregulated genes. The associated number (e.g. U1, U2 etc) refers to the rank of the specified gene. 694 
For example, CH25H is the gene found to be the most upregulated in BTV8ΔNS4 infected cells compared to 695 
mock-infected cells.  696 
 697 
 698 
  699 
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Table 2. Top 20 downregulated genes in BTV infected compared to mock-infected A549 700 
cells. 701 
BTV8ΔNS4 vs Mock BTV8wt vs Mock 
Gene Rank* Fold change Rank Fold change 
CLDND2 D1 0.13 D157 0.30
CPN1 D2 0.13 D24 0.20
DHRS4L1 D3 0.14 D425 0.38
EMID1 D4 0.14 NA** 1.0
LOC100506 D5 0.16 D3 0.15
HMOX1 D6 0.16 D4 0.15
KRT82 D7 0.16 D73 0.26
SHH D8 0.17 D5 0.15
NUPR1 D9 0.18 D11 0.18
KRT4 D10 0.18 D142 0.30
SFRP4 D11 0.19 D9 0.17
NRTN D12 0.19 NA 1.0
EMILIN1 D13 0.20 D18 0.20
LOC113230 D14 0.20 NA 1.0
LINC00086 D15 0.20 D329 0.36
OSGIN1 D16 0.21 D10 0.18
KLHDC7A D17 0.21 D1 0.12
ATOH8 D18 0.22 D2 0.14
MIR210HG D19 0.22 D106 0.28
KRTAP4-1 D20 0.22 D27 0.21
 702 
*Rank of down-regulated genes. The numbers D1, D2 etc. refers to the rank of the specified gene (the most 703 
down-regulated gene in a given condition being ranked first).  704 
**NA= not applicable as these genes have not been found to be differentially expressed in the samples 705 
considered.  706 
 707 
 708 
 709 
 710 
  711 
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FIGURES 712 
Figure 1. Experimental infection of sheep with BTV8wt and BTV8ΔNS4. Three groups of 713 
sheep (n=5 per group) were mock-infected (grey circle) or infected with either BTV8wt 714 
(black square) or BTV8ΔNS4 (black triangle). (Top panel) Body temperature (average per 715 
group) of experimentally infected sheep. Rectal temperature in sheep is normally between 716 
38.3 and 39.9°C (indicated by plain black lines). (Middle panel) BTV RNA in blood samples of 717 
experimentally infected sheep. Viral RNA was detected by qRT-PCR targeting Seg-5, and 718 
values are expressed as log10 (copy number per μg of total RNA). (Bottom panel) Box and 719 
whisker plot representing neutralizing antibodies in experimentally infected sheep at 7, 14, 720 
21 and 28 days post-infection as indicated in Materials and Methods. Grey stars (Mock 721 
versus BTV8wt) and black stars (BTV8wt versus BTV8ΔNS4). ** = p<0.01; *** = p<0.001 722 
(two-way Anova, Bonferroni post-tests). 723 
Figure 2. NS4 modulates IFN synthesis in infected cells. (A) In vitro replication kinetics of 724 
BTV8wt and BTV8ΔNS4 in primary ovine endothelial cells (ovEC) and human A549 cells. Cells 725 
were infected by BTV8wt (red) and BTV8ΔNS4 (blue) at a MOI of 0.01 and supernatants 726 
titrated at the indicated time points as described in Materials and Methods. Experiments 727 
were performed independently three times. Two-way ANOVA test, p<0.01. * = p<0.05; ** = 728 
p<0.01 (Bonferroni post-tests). (B) Upregulation of IFN-β synthesis in BTV8 infected cells. 729 
IFN protection assay. Primary ovine endothelial cells (ovEC) were mock-infected or infected 730 
with the indicated viruses (MOI=4). Supernatants were then collected at 16h pi, inactivated 731 
by UV treatment and the amount of IFN released in the supernatants determined in 732 
biological assays as described in Material and Methods. Bars in the figure represent 733 
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standard deviation. One-way Anova p=0.002. *** = p<0.001 (Tukey's Multiple Comparison 734 
Test). 735 
Figure 3. IRF-3 and NFκB nuclear translocation in BTV infected cells. A549 cells were 736 
infected at a MOI of 4 for 16h, and fixed before being processed for immunofluorescence 737 
using antibodies against NS2, IRF-3 and NFκB with an Alexa Fluor 488 secondary antibody 738 
(shown in green). Nuclei have been stained with DAPI (blue). Average values corresponding 739 
to the percentage of translocation have been indicated for each experimental condition +/- 740 
standard deviation. Scale bars correspond to 47.62 μm. 741 
Figure 4. RNAseq of BTV8wt-, BTV8ΔNS4- and mock-infected cells. A. Schematic 742 
representation of RNA sequencing workflow. A549 cells were mock-infected or infected 743 
with BTV8wt or BTV8ΔNS4 at a MOI of 4. At 12h p.i., nascent RNA was metabolically labelled 744 
with 0.4 mM of an analogue of uridine (5-ethynyl uridine, EU) for 90 m. Total RNA was 745 
extracted and enriched by selectively depleting rRNA transcripts. The EU-labelled RNA were 746 
chemically linked to an azide-modified biotin and then captured on streptavidin magnetic 747 
beads. Biotin labelled RNA attached to the magnetic beads was used directly to construct a 748 
library and subsequently sequenced using the Ion Proton sequencer. Sequence reads were 749 
processed as described in Materials and Methods. B. Plots representing differentially 750 
expressed (DE) genes according to their fold change values. Log2 fold change values >1 are 751 
regarded as upregulated (q-value < 0.05), whereas <1 is regarded as statistically 752 
downregulated (q-value < 0.05). C. Validation of RNAseq by qRT-PCR. mRNA levels of β-actin 753 
(ACTB), Annexin A1 (ANXA1), TATA-binding protein (TBP), beta-2 microglobulin (B2M), IFN-β 754 
(IFNB1) and interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) were 755 
measured by qRT-PCR at 8 and 16h pi as described in Materials and Methods. * = p<0.05; ** 756 
= p< 0.01; *** = p<0.001 (One-way Anova, Tukey's Multiple Comparison Test). 757 
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Figure 5. Cellular pathways of BTV8wt- and BTV8ΔNS4-infected cells. A-C. Canonical 758 
cellular pathways were analysed using Ingenuity Pathways Analysis. Only canonical 759 
pathways with a p-value < 6.3x105 are shown. Ratio corresponds to the number of genes 760 
found DE in a given pathway divided by the total number of genes contained in that 761 
pathway. A specific pathway is coloured in orange or blue depending on whether it has been 762 
predicted to be activated (positive z-scores) or inhibited (negative z-scores), respectively. 763 
Grey bars are pathways where no prediction can currently be made. PRR: Pattern 764 
Recognition Receptors, AII: Antiviral Innate Immunity, DC: dendritic dell, MΦ: macrophages, 765 
EC: endothelial cells, RA: rheumatoid arthritis, GC: gastric cells, NKC: natural killer cells, AR: 766 
antiviral response, OSR: oxydative stress response, DM: diabetes mellitus. A. BTV8ΔNS4 767 
versus mock-infected cells. B. BTV8wt versus mock-infected cells. C. BTV8ΔNS4- versus 768 
BTV8wt-infected cells.  769 
Figure 6. Effects of NS4 on expression driven by various promoters. CPT-Tert cells were co-770 
transfected with 100 ng of a DNA plasmid expressing either BTV10 NS2 (GenBank # 771 
NC006007), or BTV8 NS4 and a DNA plasmid expressing FLuc under the control of either 772 
CMV (50 ng), IFN-β (50 ng) or IFN-stimulated response element-containing (ISRE, 400 ng) 773 
promoter. After transfection (4h), cells transfected with the IFN-β promoter were 774 
stimulated with Sendai virus while cells transfected with ISRE-containing promoter were 775 
stimulated with universal IFN. FLuc activity was assessed 22h post-transfection in a 776 
luminometer. 5ng of capped and polyadenylated RNA made in vitro were also co-777 
transfected as a control of transfection efficiency. One-way Anova p=0.0002 (CMV), 778 
p=0.0015 (IFN-β) and p=0.0006 (ISRE). * = p< 0.05; *** = p<0.001 (Dunnett's Multiple 779 
Comparison Test).  780 
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Figure 7. NS4 from various BTV strains display inhibitory activity on gene expression. A. 781 
Multiple sequence alignment of representative NS4 sequences. Identical residues compared 782 
to BTV8 (GenBank accession # JX680455) are shown as dots. Accession numbers refer to the 783 
BTV genome segment 9 containing the NS4 open reading frame. B. CPT-Tert cells were co-784 
transfected with a plasmid expressing the indicated BTV NS4 protein (named according to 785 
the accession number corresponding to the BTV segment 9) and a plasmid expressing FLuc 786 
under the control of a CMV promoter. FLuc activity was assessed 22h post-transfection, and 787 
in parallel by western blotting analysis of the same cell lysates using anti-NS4 or anti-788 
αtubulin antibodies. One-way Anova p<0.0001. *** = p<0.001 (Dunnett's Multiple 789 
Comparison Test). C. CPT-Tert cells were co-transfected with increasing amounts of an 790 
expression plasmid for the BTV8 NS4 and a plasmid expressing the firefly luciferase (FLuc) 791 
under the control of the CMV immediate early promoter. FLuc activity was assessed 22h 792 
post-transfection in a luminometer and in parallel by western blotting of the same cell 793 
lysates using antibodies towards the NS4 or tubulin antibodies. One-way Anova p<0.0001. 794 
** = p< 0.01; *** = p<0.001 (Dunnett's Multiple Comparison Test). D. Confocal microscopy 795 
of CPT-Tert cells transfected with pCI-NS4 plasmids. At 22h post-transfection, cells were 796 
fixed and analysed by immunofluorescence using antibodies against the nucleolar marker 797 
B23 (in red) and NS4 (in green), with the appropriate conjugated secondary antibodies as 798 
described in Materials and Methods. Scale bars correspond to 33.21 μm.  799 
Figure 8. NS4 expression does not affect significantly host cellular protein shutoff, mRNA 800 
splicing or translation. A. Primary ovEC were mock-infected or infected with BTV8wt and 801 
BTV8ΔNS4 and nascent proteins were metabolically labelled with 35S-methionine/cysteine 802 
for 2 h at the time points indicated. Cell extracts were fractionated by SDS-PAGE and gels 803 
were stained with Coomassie blue. Dried gels were analysed by phosphoimaging. Black 804 
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arrow indicates cellular actin. Signal intensity quantified using the ImageQuant software. 805 
Red arrows indicate BTV proteins. B. CPT-Tert cells were co-transfected with variable 806 
amounts of plasmids expressing BTV8 NS4 protein and either a plasmid expressing FLuc 807 
under the control of a CMV promoter or a plasmid expressing renilla luciferase (RLuc) 808 
downstream an intron and the CMV promoter. FLuc or RLuc expression was assessed 22h 809 
post-transfection. Cell lysates were analysed by western blotting using antibodies towards 810 
NS4. One-way Anova p<0.0001. ** = p< 0.01; *** = p<0.001 (Dunnett's Multiple Comparison 811 
Test). C. CPT-Tert cells were co-transfected with variable amount of a DNA plasmid 812 
expressing BTV8 NS4 and either a plasmid expressing the firefly luciferase (FLuc) under the 813 
control of a CMV promoter, or capped and polyadenylated RNA made in vitro. FLuc activity 814 
was assessed 22h post-transfection. Cell lysates were also analysed by western blotting 815 
using antibodies towards NS4. One-way Anova p<0.0001. * = p< 0.05; *** = p<0.001 816 
(Dunnett's Multiple Comparison Test).  817 
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